1. Home
  2. MDXH vs ASRT Comparison

MDXH vs ASRT Comparison

Compare MDXH & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.36

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Logo Assertio Holdings Inc.

ASRT

Assertio Holdings Inc.

HOLD

Current Price

$9.72

Market Cap

75.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDXH
ASRT
Founded
2003
1995
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
75.1M
IPO Year
2021
1997

Fundamental Metrics

Financial Performance
Metric
MDXH
ASRT
Price
$3.36
$9.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$7.67
$45.00
AVG Volume (30 Days)
112.3K
30.2K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$103,069,000.00
$137,354,000.00
Revenue This Year
$23.34
N/A
Revenue Next Year
$22.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.68
9.22
52 Week Low
$1.35
$7.71
52 Week High
$5.33
$15.15

Technical Indicators

Market Signals
Indicator
MDXH
ASRT
Relative Strength Index (RSI) 43.35 93.32
Support Level $3.11 $0.61
Resistance Level $3.58 $10.42
Average True Range (ATR) 0.18 0.16
MACD 0.04 0.89
Stochastic Oscillator 52.79 90.42

Price Performance

Historical Comparison
MDXH
ASRT

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Share on Social Networks: